Human Endocrine Gland Vascular Endothelial Growth Factor Recombinant

• Background:

  This factor is identical with prokineticin-1 and is a member of the AVIT protein family. Expression of human EG-VEGF messenger RNA is restricted to the steroidogenic glands, ovary, testis, adrenal and placenta and is often complementary to the expression of VEGF. EG-VEGF has been identified as a mitogen specific for the endothelium of steroidogenic glands. EG-VEGF resembles VEGF in that it causes extensive angiogenesis and cyst formation when delivered in the ovary. EG-VEGF differs from VEGF in that it does not promote angiogenesis in the cornea or skeletal muscle. Two receptors (the G-protein-coupled receptor ZAQ and the G-protein-coupled receptor I5E) have been characterized, these receptors are expressed in gastrointestinal organs, endocrine glands and other tissues.

• Description:

  Recombinant EG-VEGF is a disulfide-linked monomer protein consisting of 87 amino acid residues, and migrates as an approximately 10 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human EG-VEGF mature chain was expressed inE. coli.

• UniProt:

  P58294

• Endotoxin:

  < 0.1 ng/µg (1 EU/µg), using the LAL gel clot method.

• Purity:

  ≥ 98% by SDS-PAGE and HPLC

• Format:

  Lyophilized protein

• Reconstitution:

  Reconstitute at 0.1-1.0 mg/ml in distilled water. This solution can then be diluted into other buffers. To maximize product collection from vial surface, vortex briefly and then spin down to recollect the liquid.

• Shipping Conditions:

  Gel Packs or Dry Ice

• Storage Conditions:

  The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C. Upon reconstitution, store in working aliquots at +4°C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein. Avoid repeated freeze/thaw cycles.

• Calculated Molecular Weight:

  10 kDa

• Formulation:

  Lyophilized from 0.2 µm filtered PBS solution.